IPO5 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4699731	1.00	2/20
SCHEMBL16111548	1.00	2/20
SCHEMBL29358745	1.00	2/20
SCHEMBL29380618	1.00	2/20
SCHEMBL29931136	1.00	2/20
SCHEMBL4697866	0.89	2/20
SCHEMBL24532075	0.89	2/20
SCHEMBL4697696	0.86	2/20
SCHEMBL23092285	0.86	2/20
SCHEMBL29688472	0.86	2/20
SCHEMBL22024695	0.86	2/20
SCHEMBL16136600	0.84	2/20
SCHEMBL24532058	0.83	2/20
SCHEMBL4699947	0.83	2/20
SCHEMBL22025026	0.82	2/20
SCHEMBL22119546	0.82	2/20
SCHEMBL24532062	0.82	2/20
SCHEMBL18804561	0.81	2/20
SCHEMBL22024561	0.81	2/20
SCHEMBL22025030	0.81	2/20

Clinical trials — most relevant to IPO5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection	PHASE3	COMPLETED
Ivermectin and Nitazoxanide Combination Therapy for COVID-19	PHASE2/PHASE3	UNKNOWN
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)	PHASE1/PHASE2	RECRUITING
Efficacy of Ivermectin in COVID-19	PHASE1/PHASE2	COMPLETED
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma	PHASE1/PHASE2	RECRUITING
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）	nan	RECRUITING
Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Pulmonary Hypertension--Mechanisms and Family Registry	nan	COMPLETED
The Influence of Genetic Variations in ELAPOR1 or ELAPOR2 on Insulin Secretion and Glucose Regulation in Humans	nan	UNKNOWN
Plasma Triglyceride Lipolysis in Multifactorial Chylomicronemia	nan	COMPLETED
Biomarker for Sanfilippo Type A-B-C-D Disease (BioSanfilippo)	nan	WITHDRAWN
MEHMO Natural History and Biomarkers	nan	RECRUITING
Genetic Analysis of Gray Platelet Syndrome	nan	COMPLETED
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)	nan	UNKNOWN
CoMPaSS-NMD - Computational Models for New Patients Stratification Strategies of HNMD	nan	ENROLLING_BY_INVITATION
Prognostic Value of Protein IMP3 Expression in Cervical Cancer	nan	COMPLETED
Chromosome 5Q Gene Variants and Asthma-Related Traits	nan	COMPLETED
Exome Analysis in Hearing Impaired Patients	nan	UNKNOWN
Mapping Novel Disease Genes for Dilated Cardiomyopathy	nan	COMPLETED
Genetic Investigation of Cancer Predisposition	nan	NOT_YET_RECRUITING
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
Identifying Genetic Causes of IC/BPS	nan	RECRUITING
New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization	nan	COMPLETED
Diagnosis of Primary Ciliary Dyskinesia	nan	COMPLETED
Linkage Study in Familial Pulmonary Fibrosis	nan	COMPLETED
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact	nan	UNKNOWN
Study of Constitutional Platelet Disease	nan	UNKNOWN
Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a IPO5 binder may also engage these)

Protein	Name	Similarity
Q8BKC5	—	1.000	Q8BKC5 →
O60518	—	0.994	O60518 →
Q8BIV3	—	0.993	Q8BIV3 →
Q91YE6	—	0.989	Q91YE6 →
IPO9	Importin-9	0.988	landscape →
Q8VI75	—	0.986	Q8VI75 →
Q7TMY7	—	0.985	Q7TMY7 →
IPO11	Importin-11	0.984	landscape →
O18388	—	0.983	O18388 →
O60100	—	0.983	O60100 →
IPO7	Importin-7	0.982	landscape →
A5WW24	—	0.982	A5WW24 →
Q9EPL8	—	0.981	Q9EPL8 →
IPO8	Importin-8	0.981	landscape →
CSE1L	Exportin-2	0.980	landscape →
Q8K2V6	—	0.979	Q8K2V6 →
XPO5	Exportin-5	0.979	landscape →
Q8AY73	—	0.979	Q8AY73 →
Q8H0U4	—	0.979	Q8H0U4 →
Q9VKY2	—	0.979	Q9VKY2 →
Q924C1	—	0.978	Q924C1 →
Q6GMY9	—	0.978	Q6GMY9 →
Q9QXK3	—	0.978	Q9QXK3 →
Q5R9J2	—	0.978	Q5R9J2 →
Q9I8E6	—	0.978	Q9I8E6 →
Q8GUL2	—	0.977	Q8GUL2 →
Q5R6L5	—	0.977	Q5R6L5 →
A5D785	—	0.977	A5D785 →
Q06142	—	0.977	Q06142 →
IPO4	Importin-4	0.977	landscape →